Prevalence and clinical relevance of occult hepatitis B in the fibrosis progression and antiviral response to INF therapy in HIV-HCV-coinfected patients

AIDS Research and Human Retroviruses

Volumn 24, Issue 4, 2008, Pages 547-553

  Laguno, Montserrat ^a   Larrousse, Maria ^a   Luis Blanco, José ^a   Leon, Agathe ^a   Milinkovic, Ana ^a   Martínez Rebozler, Maria ^a   Loncá, Montserrat ^a   Martinez, Esteban ^a   Sanchez Tapias, Jose Maria ^a   De Lazzari, Elisa ^a   Maria Gatell, José ^a   Costa, Josep ^a   Mallolas, Josep ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; HEPATITIS A ANTIBODY; HEPATITIS B CORE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; RIBAVIRIN; TENOFOVIR; VIRUS DNA;

ADULT; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE COURSE; DRUG USE; FEMALE; FIBROSIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; LIVER BIOPSY; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PREVALENCE; PRIORITY JOURNAL; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOPSY; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; DNA, VIRAL; FEMALE; HEPATITIS ANTIBODIES; HEPATITIS B; HEPATITIS B CORE ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS C, CHRONIC; HIV; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER; LIVER CIRRHOSIS; MALE; PREVALENCE; RETROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 42449105328     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.9994     Document Type: Article

References (34)

1. Raimondo G, Balsano C, Craxì A, Farinati F, Levrero M, Mondelli M, et al.: Occult hepatitis B virus infection. Digest Liver Dis 2000;32:822-826.
2. Brechot C, Thiers V, Kremsdorf D, Nalpas B, Pol S, and Paterlini-Brechot P: Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: Clinically significant or purely occult? Hepatology 2001;34:194-203.
3. Torbenson M and Thomas DL: Occult hepatitis B. Lancet Infect Dis 2002;2:479-486.
4. Shire NJ, Rouster SD, Stanford SD, Blackard JT, Martin CM, Fichtenbaum CJ, and Sherman KE: The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007;44(3):309-314.
5. Raimondo G, Pollicino T, Cacciola I, and Squadrito G: Occult hepatitis B virus infection. J Hepatol 2007;46:160-170.
6. Hu KQ: Occult hepatitis B virus infection and its clinical implications. J Viral Hepatitis 2002;9:243-257.
7. Cacciola I, Pollicino T, Squadrito G, Cerenzia G, Orlando ME, Raimondo G. Occult hepatitis B virus infection in patients with chronic hepatitis C liver disease. N Engl J Med 1999;341:22-26.
8. Gandhi RT, Wurcel A, Lee H, McGovern B, Boczanowski M, Gerwin R, Corcoran CP, Szczepiorkowski Z, Toner S, Cohen DE, Sax PE, and Ukomadu C: Isolated antibody to hepatitis B core antigen in human immunodeficiency virus type-1-infected individuals. Clin Infect Dis 2003;36:1602-1605.
9. Nunez M, Rios P, Perez Olmeda M, and Soriano V: Lack of occult hepatitis B virus infection in HIV-infected patients. AIDS 2002;16:2099-2101.
10. Neau D, Winnock M, Jouvencel AC, Faure M, Castera L, Legrand E, et al.: Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005;40:750-753.
11. Shire NJ, Rouster S, Rajicic N, and Sherman KE: Occult hepatitis B in HIV infected patients. J Acquir Immune Defic Syndr 2004;36:869-875.
12. Piroth L, Binquet C, Vergne M, Minello A, Livry C, Bour JB, Buisson M, Duong M, Grappin M, Portier H, and Chavanet P: The evolution of hepatitis B virus serological patterns and the clinical relevance of isolated antibodies to hepatitis B core antigen in HIV infected patients. J Hepatol 2002;36:681-686.
13. Hofer M, Joller Jemelka HI, Grob PJ, Luthy R, and Opravil M: Frequent chronic hepatitis B virus infection in HIV-infected patients positive for antibody to hepatitis B core antigen only. Swiss HIV Cohort Study. Eur J Clin Microbiol Infect Dis 1998;17:6-13.
14. Cooper C and Kilby D: Clinical significance of hepatitis B core antibody positivity in HCV-infected and HCV/HIV coinfected individuals. Clin Infect Dis 2004;38:1335-1337.
15. Sagnelli E, Coppola N, Scolastico C, Mogavero AR, Filippini P, and Piccinino F: HCV genotype and silent HBV coinfection: Two main risk factors for a more severe liver disease. J Med Virol 2001;64:350-355.
16. Urashima T, Saigo K, Kobayashi S, Imaseki H, Matsubara H, Koide Y, et al.: Identification of hepatitis B virus integration in hepatitis C virus-infected hepatocellular carcinoma tissues. J Hepatol 1997;26:771-778.
17. Pollicino T, Squadrito G, Cerenzia G, Cacciola I, Raffa G, Craxì A, et al.: Hepatitis B virus mantains its prooncogenic properties in the case of occult HBV infection. Gastroenterology 2004;126:102-110.
18. Zignego AL, Fontana R, Puliti S, Barbagli S, Monti M, Careccia G, et al.: Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis. J Med Virol 1997;51:313-318.
19. Scheuer PJ: Classification of chronic viral hepatitis: A need for reassessment. J Hepatol 1991;13:372-374.
20. Poynard T, Bedossa P, and Opolon P: Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR CLINIVIR and DOSVIRC groups. Lancet 1997;349:825-832.
21. Poynard T, Mathurin P, Lai CL, Gudayer D, Poupon R, Tainturier MH, et al.: A comparison of fibrosis progression in chronic liver diseases. J Hepatol 2003;38:257-65.
22. Soriano V, Barreiro P, Martin-Carbonero L, Castellares C, Ruiz-Sancho A, Labarga P, et al.: Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis 2007;195:1181-1183.
23. Neau D, Winnock M, Galperine T, Jouvencel AC, Castera L, Legrand E, Tranchant E, Balestre E, Lacoste D, Ragnaud JM, Dupon M, Lafon ME, Dabis F; Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA): Isolated antibodies against the core antigen of hepatitis B virus in HIV-infected patients. HIV Med 2004;5:171-173.
24. Santos EA, Yoshida CF, Rolla VC, Mendes JM, Vieira IF, Arabe J, and Gomes SA: Frequent occult hepatitis B virus infection in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2003;22:92-98.
25. Chemin I, Zoulim F, Merle P, et al.: High incidence of hepatitis B infections among chronic hepatitis cases of unknown aetiology. J Hepatol 2001;34:447-454.
26. Jilg W, Sieger E, Zachoval R, et al.: Individuals with antibodies against hepatitis B core antigen as the only serological marker for hepatitis B infection: High percentage of carriers of hepatitis B and C virus. J Hepatol 1995;23:14-20.
27. Jardi R, Rodriguez F, Buti M, et al.: Role of hepatitis B, C, and D viruses in dual and triple infection: Influence of viral genotypes and hepatitis B precore and basal core promoter mutations on viral replicative interference. Hepatology 2001;34:404-410.
28. Fabris P, Brown D, Tositti G, Bozzola L, Giordani MT, Bevilacqua P, et al.: Occult hepatitis B infection does not affect liver histology or response to therapy with interferon alpha and ribavirin in intravenous drug users with chronic hepatitis C. J Clin Virol 2004;29:160-166.
29. Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002;40:4068-71.
30. Nirei K, Kaneko M, Moriyama M, and Arakawa Y: The clinical features of chronic hepatitis C are not affected by coexistence of hepatitis B virus DNA in patients negative for hepatitis B surface antigen. Intervirology 2000;43:95-101.
31. Hui CK, Lau E, Wu H, Monto A, Kim M, Luk JM, Lau GK, and Wright TL: Fibrosis progression in chronic hepatitis C patients with occult hepatitis B co-infection. J Clin Virol 2006;35:185-192.
32. Scully LJ, Sung H, Pennie R, et al.: Detection of hepatitis B virus DNA in the serum of Canadian hepatitis B surface antigen negative, anti-HBc positive individuals, using the polymerase chain reaction. J Med Virol 1994;44:293-297.
33. Sanchez-Quijano A, Jauregui JI, Leal M, et al.: Hepatitis B virus occult infection in subjects with persistent isolated anti-HBc reactivity. J Hepatol 1993;17:288-293.
34. Luo KX, Zhou R, He C, et al.: Hepatitis B virus DNA in sera of virus carriers positive exclusively for antibodies to the hepatitis B core antigen. J Med Virol 1991;35:55-59.